Letter to the Editor

p21 ras-related Protein Levels Depend on Sample Handling

Armand J. Panson, Henry L. Niman, Joel L. Weissfeld, Ying Wu, and Lewis H. Kuller

Proteins immunologically related to oncogene products are detectable in plasma, serum, and urine. We and others are studying the relationship between cancer risk and circulating proteins immunologically related to the ras (1–6), c-erbB2 (7), c-myc (8), int-1 (9), and other (10) oncogene products. We recently observed that p21 ras-related plasma protein levels depend on initial sample processing methods. Plasma from blood stored at room temperature for greater than 4 h showed an increase in p21 ras relative to samples processed immediately. The increase is likely due to release from cells, related proteins, or breakdown of larger molecules.

We carried out the following experiment with plasma from healthy volunteers to investigate the effect of sample handling on immunooassay of p21 ras-related proteins. Blood was drawn from eight healthy white subjects ranging in age from 23 to 52 years, 1 male and 7 female. Five-ml lavender top EDTA tubes were used. For each subject, the blood was divided into six aliquots and each one of the aliquots was subjected to each of the following conditions before analysis: (A) plasma immediately separated; (B) plasma immediately separated and kept at room temperature 4 h; (C) blood kept at ice temperature 4 h before separating plasma; (D) blood kept at ice temperature 8 h before separating plasma; (E) blood kept at room temperature 4 h before separating plasma; or (F) blood kept at room temperature 8 h before separating plasma.

We measured p21 ras-related plasma protein levels with an immunoblot assay technique previously described (1, 11–14). The monoclonal antibody used was 142.24E05. Fig. 1 shows p21 levels as integrated optical density or absorbance. Densitometry measurements were performed with the aid of a computer-automated system. Table 1 shows mean integrated absorbance values and SDs for conditions A–F.

Table 1 Mean integrated absorbance of plasma p21 ras-related proteins

<table>
<thead>
<tr>
<th>Conditions</th>
<th>Mean integrated absorbance</th>
<th>SD</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>0.0313</td>
<td>0.0179</td>
</tr>
<tr>
<td>B</td>
<td>0.0209</td>
<td>0.0143</td>
</tr>
<tr>
<td>C</td>
<td>0.0293</td>
<td>0.0171</td>
</tr>
<tr>
<td>D</td>
<td>0.0638</td>
<td>0.0461</td>
</tr>
<tr>
<td>E</td>
<td>0.143</td>
<td>0.0576</td>
</tr>
<tr>
<td>F</td>
<td>0.147</td>
<td>0.0768</td>
</tr>
</tbody>
</table>

levels from blood processed according to conditions B, C, and D did not differ statistically from the control condition. Therefore, we observed substantial effects of sample handling procedures on plasma levels of p21 ras-related proteins. These effects are clearly large enough to threaten the validity of epidemiological or clinical studies, particularly studies which entail separate sample collections from unique populations dispensed over time or place. We suspect that many other candidate cancer biomarkers may be susceptible to similar artifacts. Therefore, all reports pertaining to new cancer biomarkers should include a complete description of sample collection and storage procedures.

References


Received 1/4/94; accepted 1/21/94.

To whom requests for reprints should be addressed, at Pittsburgh Cancer Institute, L10 Keystone Building, 3520 Fifth Avenue, Pittsburgh, PA 15213.


p21 ras-related protein levels depend on sample handling.
A J Panson, H L Niman, J L Weissfeld, et al.


Updated version  Access the most recent version of this article at:
http://cebp.aacrjournals.org/content/3/3/281.citation

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.
Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.
Permissions  To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.